BAUSCH + LOMB CORP (BLCO)

CA0717051076 - Common Stock

17.47  +0.23 (+1.33%)

BAUSCH + LOMB CORP

NYSE:BLCO (1/15/2025, 9:38:20 AM)

17.47

+0.23 (+1.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS SubIndustryHealth Care Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-22.73%
Sales Q2Q%18.77%
CRS52.58
6 Month1.53%
Overview
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)N/A N/A
Ins Owners0.29%
Inst Owners11.91%
Market Cap6.15B
Shares352.17M
PE28.64
Fwd PE20.25
Dividend YieldN/A
Analysts73
Short Float %3%
Short Ratio2.64
IPO05-06 2022-05-06
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BLCO Daily chart

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,300 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Company Info

BAUSCH + LOMB CORP

520 Applewood Crescent

Vaughan ONTARIO

P: 19082552864

Employees: 13300

Website: https://ir.bausch.com/

BLCO News

News Imagea day ago - Market News VideoBLCO Crosses Below Key Moving Average Level
News Image2 days ago - Bausch + Lomb CorporationBausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
News Image2 days ago - Bausch + Lomb CorporationBausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
News Image8 days ago - Bausch + Lomb CorporationBausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
News Image13 days ago - Bausch + Lomb CorporationBausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Imagea month ago - BloombergBausch + Lomb Confirms It Is Exploring a Potential Sale

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private equity firms.

BLCO Twits

Here you can normally see the latest stock twits on BLCO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example